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Abstract
Background. New-onset diabetes after transplantation
(NODAT) is associated with poorer outcomes in kidney
transplantation (KT). Thus, identification of modifiable
risk factors may be crucial for ameliorating the impact of
this entity on transplant outcomes. We assessed the rela-
tionships between the weight, body mass index (BMI)
and weight gain with NODAT.
Methods. We retrospectively analysed 2168 KT performed
in Spain during 1990, 1994, 1998 and 2002, with a func-
tioning graft after the first year. At 1 year after KT, three
groups were considered: (i) NODAT group (n = 215); (ii)
impaired fasting glucose (IFG) group (n = 389); (iii) con-
trol group (n = 1564).
Results. The incidence of NODAT was 10.8%, 9.9% and
10.0% at 3, 12 and 24 months post-transplantation, respec-
tively. Older recipient age (P < 0.0001) and greater use of
tacrolimus (P < 0.0001) were observed in NODAT group.
Obesity was more frequent in NODAT group (P < 0.0001),
but patients with NODAT had a lower weight gain during
the first year after KT (P = 0.038). On multivariate analy-
sis, independent risk factors associated with the develop-
ment of NODAT were: recipient age [odds ratio (OR):
1.060, P = 0.0001], tacrolimus (OR: 1.611, P =0 . 0 0 5 ) ,
triglycerides (OR: 1.511, P = 0.018), positive hepatitis C
virus (HCV) status (OR: 1.969, P = 0.001) and pre-trans-
plant body mass index (BMI) (OR: 1.135, P = 0.0001), but
not the weight gain.
Conclusions. BMI, but not the weight gain at 1year after
transplant, is an independent risk factor for NODAT. Tai-
loring clinical strategies may minimize the impact of this
complication.
Keywords: diabetes post-transplant; kidney transplantation; NODAT;
weight gain
Introduction
New-onset diabetes after transplant (NODAT) is a fre-
quent entity in kidney transplant recipients [1], and it
is associated with poor outcomes. Prospective and ret-
rospective studies have concluded that NODAT is an
independent predictor of global mortality, graft failure
and death-censored graft failure [1–4]. Identification
of those potentially modifiable risk factors may help
to create strategies in order to improve transplant
outcomes.
NODAT has been related to both non-modifiable and
modifiable risk factors such as age, ethnic, genetic back-
ground, gender, family history of diabetes, hepatitis C
virus infection, cytomegalovirus (CMV) infection, im-
munosuppressive drugs and overweight [1,5–9]. In par-
ticular, body weight and body mass index (BMI) have
been shown to be associated with post-transplant diabe-
tes in most studies [4,7]. Moreover, the weight gain after
kidney transplantation (KT) is common and is attribut-
able mainly to inappropriate dietary habits, decreased
physical activity and steroid use [10]. Because weight
gain is a risk factor for an insulin-resistant state in gen-
eral population, it is plausible to think that this risk fac-
tor could be associated with NODAT. However, the
relationship between NODAT and weight gain during
the first post-transplant year remains undetermined.
While some investigators have reported a significant as-
sociation between NODAT and weight gain, others have
not [1,11–17].
The aim of the present study was to assess the relation-
ships between anthropometric parameters such as pre-
transplant weight, BMI and weight gain at the first post-
transplant year with NODAT at 12 months post-transplan-
tation in a large cohort of KT recipients.
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Study design
We conducted a retrospective cohort study with patients receiving a kid-
ney allograft in 34 Spanish centres during four different years (1990,
1994, 1998 and 2002), with a last follow-up in December 2005. The study
design has been previously reported [18]. Patients with age under 18 years,
those with graft loss during the first year, patients who had a diagnosis of
diabetes mellitus prior to transplant and those for whom data were not
available were excluded for this study.
Clinical variables
The following variables were evaluated at time of transplantation: source
of the organ (living or deceased), cause of donor death, age and gender of
the donor and of recipient, presence of hepatitis B surface antigen and
hepatitis C virus (HVC) antibodies in the donor and recipient, cause of
end-stage renal disease (ESRD), time on dialysis, panel-reactive antibo-
dies, number of human lymphocyte antigen (HLA) mismatches, and cold
ischaemia time. After transplantation, the following variables were re-
corded: immunosuppressive treatment by intention to treat, presence of
delayed graft function (defined as haemodialysis requirement after the
first week of surgery once rejection, vascular complications or urinary
obstruction were ruled out) and acute rejection. At 3 months and yearly
thereafter, the following variables were recorded: serum creatinine, gly-
caemia, total cholesterol, triglycerides, 24-h proteinuria, weight and blood
pressure. The use of hypoglycaemic therapy was also recorded.
Medical record review was performed according to Spanish law with
reference to clinical data confidentiality protection. The study was ap-
proved by each of the participating hospitals and was conducted in accor-
dance with the provisions of the Declaration of Helsinki.
Definition of variables
NODAT was diagnosed according to the 2003 international consensus
guidelines for new-onset diabetes after transplantation [5]: fasting plasma
glucose ≥126 mg/dL on two separate occasions or casual plasma glucose
≥200 mg/dL with symptoms, or the need for insulin/oral hypoglycaemic
agents treatment. Glucose levels between 100 and 125 mg/dL were diag-
nostic of impaired fasting glycaemia (IFG). Glucose levels lower than 100
without treatment were considered as normal or normoglycaemia. The to-
tal sample was subdivided into three groups that take account the glucose
metabolism alterations at 1year after transplantation: (i) patients with NO-
DAT (NODAT group); (ii) patients with IFG (IFG group); and (iii) nor-
moglycaemic patients (control group or normoglycaemic group).
BMI was calculated as body weight in kilograms divided by square of
their height in metres. Obesity was defined as a BMI ≥30 kg/m
2,a n d
overweight as a BMI between 25 and 30 kg/m
2. A BMI <25 was defined
as control BMI.
Theweight gain at 12 months after transplantation was calculated as the
difference between theweight at 12 months and theweight at time of trans-
plantation (basal weight). Similarly, the percentage increase (delta) at the
first year was calculated as the difference between the weight at 12 months
and the basal weight, divided by the basal weight and multiplied by 100.
Statistical analysis
Descriptive results are expressed as mean ± SD for continuous variables.
Frequency and contingency tables were used to describe categorical and
ordinal variables. Comparison between groups was performed by chi-
square test for categorical data. For numeric data, ANOVA or Kruskal–
Wallis for normal or non-normal distribution was employed, respectively,
with Bonferroni adjustments for pairwise. Multiple logistic regression
analyses were carried out to identify risk factors for NODAT at the first
Table 1. Baseline characteristics and the follow-up data of NODAT, IFG and control patients at the time of transplantation
All NODAT IFG Control P-value
a
Number of patients 2168 215 389 1564
Donor characteristics
Age (year) 42 ± 17 46 ± 17 45 ± 17 41 ± 17
b, c 0.0001
Gender (% male) 66.3 65.1 69.9 65.5 NS
Living donors (%) 2.0 1.9 1.6 2.1 NS
Recipient characteristics
Age (year) 46 ± 13 55 ± 9 50 ± 12
b 44 ± 13
b, c 0.0001
Gender (% male) 63.1 57.7 70.7
b 61.9
c 0.001
Primary cause of ESRD (%)
Glomerulonephritis 23.7 12.1 21.1
b 25.9
b, c 0.0001
Polycystic 13.5 16.3 15.7 12.6 NS
Other/unknown 62.8 71.6 63.2
b 61.5
b 0.016
Time on dialysis (months) 42.7 ± 47.1 38.8 ± 41.7 39.0 ± 42.5 44.1 ± 48.8 NS
HCV antibodies (% positive) 14.2 17.7 9.8
b 14.8
c 0.012
Year of transplant 2002 (%) 29.0 41.4 33.1
b 26.3
b, c 0.0001
HLA mismatches 3.1 ± 1.2 3.3 ± 1.2 3.1 ± 1.2 3.1 ± 1.2 NS
Cold ischaemia time (h) 18.8 ± 6.2 18.7 ± 6.0 19.0 ± 6.3 18.7 ± 6.3 NS
Immunosuppression (%)
Cyclosporine-based 72.4 63.2 63.3 76
b, c 0.0001
Tacrolimus-based 24.3 33.0 33.2 20.8
b, c 0.0001
Anti-mTOR-based 3.3 6.6 3.7
b 2.8
b 0.014
Delayed graft function (%) 28.3 27.4 29.3 28.2 NS
Acute rejection (%) 29.2 25.4 24.1 31
b, c 0.012
SCr at 1 year (mg/dL) 1.6 ± 0.6 1.5 ± 0.5 1.6 ± 0.6 1.6 ± 0.6 NS
Proteinuria at 1 year (g/day) 1.1 ± 0.5 1.2 ± 0.5 1.1 ± 0.4 1.1 ± 0.5 NS
TGD >200 mg/dL (%) 20.6 28.4 24.3 18.6
b, c 0.001
Steroid withdrawal at 1 year (%) 5.3 7.4 10.3 3.7
b, c 0.0001
NODAT, new-onset diabetes after transplantation; IFG, impaired fasting glucose; BMI, body mass index; ESRD, end-stage renal disease; HCV , hepatitis
C virus; PRA, panel-reactive antibodies; HLA, human lymphocyte antigen; mTOR, mammalian target of rapamycin; SCr, serum creatinine; TGD,
triglycerides.
aKruskal–Wallis or ANOVA (continuous variables), chi-square (categorical variables).
bSignificant differences compared with NODAT.
cSignificant differences compared with IFG.
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found to be significant in previous univariate analyses and those potential
confounder variables. Finally, we analysed the effect of potential interac-
tions between weight gain during the first year and the BMI at time of
transplantation (basal BMI). Statistical analyses were performed with
SPSS software version 16.0 (SPSS, Inc., Chicago, IL). A P-value <0.05
was considered significant.
Results
A total of 5060 patients, who received a KT in 34 Spanish
centres during 1990, 1994, 1998 and 2002, were initially
considered. We excluded those with age lower than
18 years (n =131), those with graft loss or death with func-
tioning graft during the first year (n = 427), those with di-
abetes mellitus prior to KT (n = 268) and those for whom
data for BMI calculation were not fully available (n =
2066). Finally, 2168 renal transplant patients fulfilling
the inclusion criteria were studied. Of these patients, at 1
year after KT, there were 215 patients in NODAT group
(9.9%), 389 in IFG group (17.9%) and 1564 in control
group (72.1%). The median of follow-up was 6.8 years (in-
terquartile range: 4.1–8.6 years).
The baseline characteristics and the follow-up data of
donor and recipients, in the three groups, are provided in
Table 1. In the control group, donor and recipients were
younger and had a lower proportion of patients trans-
planted in 2002 compared with the other years. A higher
incidence of acute rejection with a lower proportion of ta-
crolimus-based therapy and a lower proportion of steroids
withdrawal at 1year were also observed in this group. A
lower percentage of glomerulonephritis as primary disease
and a higher proportion of HCV antibodies positive were
found in the NODAT group, while hypertriglyceridaemia
(>200 mg/dL) at 3 months after transplant was more fre-
quently seen in NODAT and IFG groups.
Frequency of NODAT and IFG
Figure 1 shows the prevalence of IFG and NODATat 3, 12
and 24 months after transplantation. NODAT was ob-
served in 234 (10.8%), 215 (9.9%) and 209 (10.0%) reci-
pients at 3, 12 and 24 months post-transplantation,
respectively. Likewise, IFG was found in 414 (19.1%),
389 (17.9%) and 388 (18.6%) recipients at 3, 12 and
24 months, respectively.
Figure 1 also shows the clinical changes of each group
during the first 2 years after transplantation. The majority
of recipients, 88% of control (normoglycaemic patients),
41% of IFG and 63% of NODAT, remained in the same
group from 3 to 12 months. However, a total of 24% of
patients with NODAT at 3 months after transplant be-
came IFG patients at 12 months after transplant, whereas
13% normalized to control patients at 1year after
transplantation.
Similarly, a large percentage of patients in the IFG
group at 3 months experienced changes during the fol-
low-up, either to NODATor to control group. More specif-
ically, 47% of patients with IFG at 3 months became
control patients at 12 months after transplant. Neverthe-
less, 12% of patients with IFG at 3 months evolved to NO-
DAT at 12 months. Finally, only 1% of patients from
control group at 3 months developed NODATat 12 months,
and up to 11% patients in control group at 3 months had
IFG at 12 months.
The same results were shown when the clinical changes
between 12 and 24 months were taken into account. Inter-
estingly, the percentage of patients that recovered NODAT
or IFG was higher between 3 and 12 months post-trans-
plantation than between the first and second year.
Of note, the patients that improved from NODAT group
at 3 months, either to IFG or control group at 12 months,
had a lower age at transplantation (52.6 ± 11.1 vs. 55.6 ±
Fig. 1. Glucose metabolism change status from 3 to 24 months after transplantation. Patients who remained in the same group (solid lines), patients
who improved (dashed lines) and patients whose previous clinical situation worsened (dotted lines). Others (asterisk) group includes patients with end
of follow-up between 1 and 2years after transplantation (n = 78).
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change. In the same way, the patients that, at 12 months,
returned to control group from IFG at 3 months after trans-
plant were younger (46.2 ± 11.0 versus 52.1 ± 13.5 years
at transplantation, P < 0.001) than the patient who did not
recover.
BMI and weight gain
Mean BMI was 24.4 ± 4.0 kg/m
2 at the time of transplant,
25.2 ± 3.8 kg/m
2 at 3 months after transplantation and
26.3 ± 4.2 kg/m
2 at 1year after KT. At the time of trans-
plant, 60.1% patients had a normal BMI, with 30.9%
overweight, and 9% were obese. At 1year after transplan-
tation, the percentage of patients with a normal BMI had
decreased to 41.6%, and the percentage of patients with
overweight or with obesity had increased to 40.9%
and 17.5%, respectively.
During the first year post-transplantation, 1691 (78.8%)
patients gained weight, while 477 (21.2%) had weight loss.
The mean weight gain was 5.0 ± 6.3 kg (range between
−29 and 37 kg), and the mean weight gain delta was
8.2 ± 7.4% (range between −36% and 61%). Excluding
those patients who have lost weight, the mean of gain
weight and weight gain delta were 7.2 ± 4.9 kg and
11.6 ± 8.2%, respectively. Furthermore, 39.7% of the pa-
tients gained between 0% and 10%, and 39.1% gained
>10% of their baseline weight. The weight gain was in-
versely associated with baseline BMI; that is, the patients
with normal BMI at transplantation showed a higher weight
gain at 1year after transplantation compared with patients
with overweight and obesity (6.0 ± 5.7; 4.3 ± 6.5; and 1.7 ±
8.4 kg, respectively, P < 0.001). These differences re-
mained significant whentheweight gain deltawas analysed
(10.2 ± 9.9% for control BMI, 6.1 ± 8.8% for overweight
and 2.13 ± 10.0% for obese patients; P < 0.001).
Figure 2 and Table 2 show the relationship between
BMI, weight, and weight gain with NODAT, IFG or con-
trol status. NODAT group had a higher BMI, at time of
KT, than IFG or control groups. Notably, the percentage
of patients with obesity was higher in NODAT group with
respect to IFG and control group (24.2%, 10.8% and 6.5%,
respectively).
At the first post-transplant year, the patients with NO-
DAT had a weight gain of 6.4 ± 10 compared with 8.5 ±
9.9 and 8.4 ± 10 in the IFG or control group, respectively
(P = 0.038). In other words, the percentage of patients who
had a weight loss during the first year of transplantation
was lower in control and IFG groups compared to NODAT
group, but these differences were not significant.
Fig. 2. Relationship between delta of weight gain versus NODAT, IFG or
control group. Data are expressed as median and quartiles. Median
NODAT group: 5.7%; median IFG group: 7.5%; median control group:
7.6%. Kruskal–Wallis.
Table 2. Weight and BMI changes of NODAT, IFG and control patients during the first year after transplantation
NODAT IFG Control P-value
a
Number of patients 215 389 1564
Basal weight (kg) 70.6 ± 12.8 69.6 ± 12.4 65.0 ± 12.0
b, c 0.0001
Basal BMI (kg/m
2) 27.0 ± 4.7 25.2 ± 3.7
b 23.9 ± 3.8
b, c 0.0001
BMI <25 kg/m




2 (%) 37.2 40.1 27.7
b, c 0.0001
BMI >30 kg/m
2 (%) 24.2 10.8
b 6.5
b, c 0.0001
Weight at 1 year (kg) 74.6 ± 13.7 75.0 ± 12.6 70.2 ±
b,c 0.0001
BMI at 1 year (kg/m
2) 28.5 ± 5.1 27.2 ± 3.8
b 25.8 ± 4.0
b,c 0.0001
BMI <25 kg/m
2 (%) 28.8 29.5 46.3
b, c 0.0001
BMI 25–30 kg/m




2 (%) 32.8 22.7
b 14.2
b,c 0.0001
Weight gain at 1 year (kg) 4.2 ± 6.9 5.4 ± 6.5
b 5.1 ± 6.1 NS
Weight gain >10 kg (%) 19.4 21.1 18 NS
Weight gain 0–10 kg (%) 53.9 58.3 61.4 NS
Weight gain <0 kg (%) 26.7 20.6 20.6 NS
Delta weight gain at 1 year 6.4 ± 10.0 8.5 ± 9.9
b 8.4 ± 10.0
b 0.038
Delta weight gain >25% (%) 3.9 6.6 5.4 NS
Delta weight gain >10% (%) 34.0 39.8 39.6 NS
Delta weight gain 0–10% (%) 39.3 39.6 39.8 NS
Delta weight gain <0% (%) 26.7 20.6 20.6 NS
NODAT, new-onset diabetes after transplantation; IFG, impaired fasting glucose; BMI, body mass index.
aKruskal–Wallis or ANOVA (continuous variables), chi-square (categorical variables).
bSignificant differences compared with NODAT.
cSignificant differences compared with IFG.
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at 1year after KT had a lower percentage of obesity at
transplantation (7.1% vs. 26.9%, P = 0.012) compared
with those who did not recover. Similarly, the patients that,
at 12 months after KT, returned to control group from IFG
at 3 months after transplant were thinner (BMI: 24.1 ± 3.9
versus 25.7 ± 3.9 kg/m
2 at transplantation, P < 0.001) than
the patient who did not recover. No association between
weight gain during the first year after transplantation and
recovery of NODAT or IFG was observed.
Variables associated with NODAT
Results of the multivariate logistic regression analysis, us-
ing NODATat 1year after transplantation as dependent var-
iable, are provided in Table 3. Independent clinical risk
factors associated with the development of NODATwere:
recipientage,pre-transplantBMI,useoftacrolimus,triglyc-
eride levels at 3months (>200 mg/dL) and HCV status.
However, the weight gain during the first post-trans-
plant year was not associated with NODAT in the multi-
variate analysis. No changes were observed in the odds
ratio when weight gain was eliminated from the model.
Therefore, no interaction between BMI and weight gain
was demonstrated.
Discussion
In the present study, we showed that pre-transplant BMI,
but not weight gain during the first post-transplant year,
makes up an important risk factor for the development
of NODAT. Additionally, other risk factors for this entity
were age, use of tacrolimus, triglycerides and HCV status
as reported previously [1,4,19–21]. To our knowledge, this
is one of the largest observational multi-centre studies as-
sessing the influence of weight gain and baseline BMI on
the development of diabetes post-transplantation.
Like other studies, we have demonstrated the relation-
ship between weight and body mass index with NODAT
[1,4,6]. Up to 24% of patients who developed NODAT
were obese at the time of transplantation, and the risk of
NODAT increased 13% for each increase of one unit of
BMI, after adjusting for other confounder variables. It is
also well known about the relation between weight gain
and renal transplantation. Patients who received a KT ex-
perience weight gain after the transplantation. In our study,
there was an increase of 8.2% of basal weight at 1year af-
ter transplantation, which is similar to other studies
[10,22]. We found a trend towards lower weight gain in
the NODAT group. However, weight gain was not an in-
dependent predictor for NODAT in multivariate analysis.
In agreement with our results, Cosio et al. found a sig-
nificant correlation between pre-transplant weight and
NODAT, but not with weight gain, in patients who re-
ceived cyclosporine-based immunosuppression [1]. In ad-
dition, previous reports have documented a significantly
lower weight gain during the first post-transplant year in
patients who developed NODAT [12,13]. The reasons for
a lower weight gain in patients with NODATare not entire-
ly clear. It is possible that patients with NODAT may have
underlying metabolic disorders which prevent weight in-
crease. At the same time, it is possible that a strict dietary
control or a more rapid reduction of steroids was per-
formed in NODAT group. Unfortunately, we did not record
further clinical data, such as dose of steroids, or data of
starting diabetes for supporting this hypothesis.
In contrast, several other studies have reported that
weight gain is associated with NODAT [15–17]. Method-
ological differences may explain, at least in part, the appar-
ent result disparity. Many of these studies used an
increased post-transplant BMI as a surrogate for weight
gain, which may lead to misleading results. We calculated
for each patient the weight gain as an independent variable
that allowed us accurately to estimate weight gain. In ad-
dition, some of these investigations did not include pa-
tients under tacrolimus-based immunosuppression.
The results of our study also differ from those found in
non-transplantation population [11]. In fact, lifestyle mod-
ification and reduction of weight have been shown to re-
duce the risk for type 2 diabetes in the general population
[23]. Some reasons may account for these controversial
findings. The negative effect of weight gain may be
masked by other risk factors for NODAT inherent to KT,
such as immunosuppression or HCV status. Accordingly,
use of tacrolimus, triglycerides levels and HCV status were
associated with the risk for NODAT in our study. In addi-
tion, it is plausible that the effect of weight gain for devel-
oping diabetes requires a longer term. As a matter of fact,
in the general population, an association has been observed
between duration of obesity and risk of non-insulin-depen-
dent diabetes mellitus [24].
In agreement with previous reports, we found that the
changes from NODAT to IFG or normal status were not
uncommon [25,26]. Although most patients remained in
the same group, 37% of NODAT patients at 3 months after
KT became IFG or normoglycaemic (control patients) at
12 months. Interestingly, in our study, this change was re-
lated to younger and lower BMI patients. These findings
reinforce the hypothesis that, in predisposed patients, fur-
ther factors such as immunosuppression would favour the
Table 3. Multivariate analysis for NODAT at 1year after transplantation
OR (95% CI) P
Model with weight gain
BMI (kg/m
2) 1.135 (1.093–1.178) 0.0001
Recipient age (years) 1.060 (1.045–1.075) 0.0001
Triglycerides (vs. <200 mg/dL) 1.511 (1.072–2.131) 0.018
Tacrolimus (vs. cyclosporine) 1.611 (1.156–2.246) 0.005
Hepatitis C antibody positive 1.969 (1.309–2.961) 0.001
Delta weight gain (%) 1.012 (0.996–1.029) 0.145
Model without weight gain
BMI (kg/m
2) 1.130 (1.091–1.170) 0.0001
Recipient age (years) 1.059 (1.044–1.073) 0.0001
Triglycerides (vs. <200 mg/dL) 1.507 (1.075–2.112) 0.017
Tacrolimus (vs. cyclosporine) 1.623 (1.174–2.245) 0.003
Hepatitis C antibody positive 1.923 (1.287–2.873) 0.001
Also adjusted for: gender, primary cause of ESRD, year of transplanta-
tion, HLA mismatches, acute rejection, anti-mTOR-based therapy, ster-
oids withdrawal at 1 year after kidney transplant, renal function.
NODAT, new-onset diabetes after transplantation; BMI, body mass index
at transplantation.
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tients with lesser predisposition at time of transplant, as
younger and thinner, the action of those additional factors
could be recovered.
This study has some limitations. It is a retrospective
study. All retrospective studies have the potential for recall
bias. However, the case selection and data collection were
rigorous and complete. Because we believe that the BMI is
a better marker of obesity than weight, we preferred to in-
clude in the study only those patients with this value. In the
present study, the incidence of NODAT at 1 year of trans-
plant was 10%, using the 2003 international consensus
guidelines for this metabolic alteration. In addition, we
did not perform in our patients an oral glucose tolerance
test for unmasking metabolic disorders. Thus, this ap-
proach may underestimate the true incidence of this disor-
der, and prospective studies are needed to clarify these
aspects.
We conclude that the baseline BMI, but not the weight
gain in the first year after transplant, is an independent
risk factor for the development of NODAT. If reduction
in weight prior to transplantation or the use of a particular
immunosuppression in patients at high risk for NODAT
could reduce the incidence of NODAT remains to be
demonstrated.
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